---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-026988"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:07:56.184677+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Avalo Q2 2023: AVTX-002 misses Phase 2 asthma endpoint; cash $6.3M, debt forbearance

## Summary
- AVTX-002 did not meet primary endpoint (asthma-related events) in Phase 2 PEAK non-eosinophilic asthma trial.
- Net loss of $8.2M for Q2 2023; product revenue of $643K.
- Cash $6.3M at June 30, 2023, down from $13.2M at Dec 31, 2022; $6M loan prepaid in June.
- Forbearance agreement with lenders until Aug 15, 2023 due to material adverse change event of default.
- Exploring sale or out-licensing of assets; non-binding LOI for AVTX-801/802/803.

## SEC filing metadata
- accession: 0001628280-23-026988
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023026988/0001628280-23-026988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023026988/avtx-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-026988
- JSON: https://secwatch.observer/filing/0001628280-23-026988.json
- Plain text: https://secwatch.observer/filing/0001628280-23-026988.txt

## Key facts
- Earnings Releases
  Avalo Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Avalo Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023026988/0001628280-23-026988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.